Dr. Reddy's Laboratories Ltd Common Stock (RDY)
Healthcare › Pharmaceutical Preparations
Price History
Feb 9, 2026 — Jul 6, 2026Investment Snapshot
- Trading 66% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 2/9 — signs of financial weakness
- ROE of 17.0% — good return on equity
- Revenue growing at 14% annually
Dr. Reddy's Laboratories Ltd Common Stock (RDY) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NYSE , with a market capitalisation of $12.8 billion . Key value metrics: P/E ratio 19.1, P/B ratio 3.25, Piotroski F-Score 2 out of 9 .
Value Score
Key Metrics
Dr. Reddy's Laboratories Ltd Common Stock — Fundamental Analysis Summary
Dr. Reddy's Laboratories Ltd Common Stock (RDY) is currently trading 66% above its Graham Number of $9.25, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries a reasonable trailing P/E ratio of 19.1x.
On financial health, RDY shows a weak Piotroski F-Score of 2/9, a signal of deteriorating financial health, and solid return on equity of 17.0% (sector average: -20.6%), and manageable leverage with a debt-to-equity ratio of 0.46.
StockPik's composite Value Score for RDY is 60/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
RDY reports a solid gross margin of 58.5% (sector average: 39.4%) and a strong operating margin of 22.1%.
RDY shows revenue growing at 14% year-over-year, with earnings growing at 0%.